Evidence map›Paper›PMID 24332926›Full record

ReviewCytokine & growth factor reviews2014

Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.

Prakash Vempati, Aleksander S Popel, Feilim Mac Gabhann

Abstract readReview
In one paragraph

Review in Cytokine & growth factor reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers.

0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

144 citing papers in PubMed, 313 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Metformin-loaded J-AuPPS for infected diabetic wound treatment.Frontiers in bioengineering and biotechnology · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. The role of MMPs in intracerebral hemorrhage.Frontiers in cell and developmental biology · 2025
    Review

84 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Prakash VempatiDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Aleksander S PopelDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Feilim Mac GabhannInstitute for Computational Medicine and Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21218, USA. Electronic address: feilim@jhu.edu.
Johns Hopkins University · USJohns Hopkins Medicine · US

Funding

Systems Biology of Angiogenesis in Peripheral Arterial DiseaseR01HL101200 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI POPEL, ALEKSANDER S. · 2010 to 2022
$10.7M
Predictive experiment-based multiscale models of the tumor immune microenvironment and immunotherapy in breast cancerR01CA138264 · NCI · JOHNS HOPKINS UNIVERSITY · PI POPEL, ALEKSANDER S. · 2009 to 2023
$8.1M
Endothelial cell decisions integrate soluble and matrix-bound VEGF gradientsR00HL093219 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI MAC GABHANN, FEILIM C · 2009 to 2011
$746k
NCI NIH HHS R01 CA138264NHLBI NIH HHS R00 HL093219NHLBI NIH HHS R01 HL101200
6 · The paper itself

Abstract

The regulation of vascular endothelial growth factor A (VEGF) is critical to neovascularization in numerous tissues under physiological and pathological conditions. VEGF has multiple isoforms, created by alternative splicing or proteolytic cleavage, and characterized by different receptor-binding and matrix-binding properties. These isoforms are known to give rise to a spectrum of angiogenesis patterns marked by differences in branching, which has functional implications for tissues. In this review, we detail the extensive extracellular regulation of VEGF and the ability of VEGF to dictate the vascular phenotype. We explore the role of VEGF-releasing proteases and soluble carrier molecules on VEGF activity. While proteases such as MMP9 can 'release' matrix-bound VEGF and promote angiogenesis, for example as a key step in carcinogenesis, proteases can also suppress VEGF's angiogenic effects. We explore what dictates pro- or anti-angiogenic behavior. We also seek to understand the phenomenon of VEGF gradient formation. Strong VEGF gradients are thought to be due to decreased rates of diffusion from reversible matrix binding, however theoretical studies show that this scenario cannot give rise to lasting VEGF gradients in vivo. We propose that gradients are formed through degradation of sequestered VEGF. Finally, we review how different aspects of the VEGF signal, such as its concentration, gradient, matrix-binding, and NRP1-binding can differentially affect angiogenesis. We explore how this allows VEGF to regulate the formation of vascular networks across a spectrum of high to low branching densities, and from normal to pathological angiogenesis. A better understanding of the control of angiogenesis is necessary to improve upon limitations of current angiogenic therapies.

Indexed as

Alternative SplicingAnimalsExtracellular MatrixFibrinolysinGene Expression RegulationHeparan Sulfate ProteoglycansHumansMatrix MetalloproteinasesMiceNeoplasmsNeovascularization, PathologicNeovascularization, PhysiologicNeuropilin-1Protein IsoformsProteolysisVascular Endothelial Growth Factor AFibrinolysinHeparan Sulfate ProteoglycansMatrix MetalloproteinasesNeuropilin-1Protein IsoformsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1VEGFA protein, humanAngiogenesisComputational modelExtracellular matrixGradientMathematical modelMicroenvironmentProteaseReceptorSystems biology

Identifiers

PMID24332926
PMCPMC3977708
OpenAlexW1994719482

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.